Drugs / Ba253MDI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02182583 Comparator | Oct 1998 → Jun 2000 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ba253MDI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02182583 ↗ |
| Known as | Tersigan aerosol | “The objective of this study is to investigate the efficacy and safety of Ba253BINEB during the continuous 4 weeks administration to the patients with COPD using Ba253MDI...” NCT02182583 ↗ |